Keywords: unimed, acquires, rights, searle, maxaquin, pharmaceuticals, acquired

Unimed Acquires US Rights To Searle's Maxaquin

Article | 24 February 1997

- Unimed Pharmaceuticals has acquired long-term exclusive USmarketing and distribution rights to Searle's fluoroquinolone anti-infective Maxaquin (lomefloxacin), indicated for the prevention ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Lomefloxacin Hcl

Maxaquin

Go to drug listing